PRESS RELEASE published on 05/19/2025 at 07:51, 10 months 18 days ago AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la propriété intellectuelle AB Science reçoit un brevet chinois pour le masitinib dans le traitement du COVID-19 jusqu'en 2041, renforçant sa protection en propriété intellectuelle COVID-19 Propriété Intellectuelle AB Science Masitinib Brevet Chinois
PRESS RELEASE published on 05/19/2025 at 07:51, 10 months 18 days ago AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection AB Science receives Chinese patent protecting masitinib in the treatment of COVID-19 until 2041, providing long-term intellectual property protection. Collaboration with University of Chicago for COVID-19 research Intellectual Property COVID-19 Treatment AB Science Masitinib Chinese Patent
BRIEF published on 05/01/2025 at 10:11, 11 months 5 days ago AB Science reporte la publication de son rapport financier annuel 2024 Euronext Paris Rapport Financier Publication Retardée AB Science Masitinib
BRIEF published on 05/01/2025 at 10:11, 11 months 5 days ago AB Science postpones the publication of its 2024 annual financial report Euronext Paris Financial Report Publication Delayed AB Science Masitinib
PRESS RELEASE published on 05/01/2025 at 10:06, 11 months 5 days ago AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025 AB Science annonce le report de la publication de son rapport financier annuel 2024 au 9 mai 2025 pour achever l'audit. La société se spécialise dans les inhibiteurs de protéines kinases Rapport Financier Audit AB Science Masitinib Inhibiteurs De Protéines Kinases
PRESS RELEASE published on 05/01/2025 at 10:06, 11 months 5 days ago AB Science will publish its 2024 annual financial report on May 9, 2025 AB Science postpones the publication of its 2024 annual financial report to May 9, 2025, to allow auditors more time for audit work. The report will be released after trading hours Financial Report Postponement Auditors AB Science 2024 Annual Report
BRIEF published on 04/23/2025 at 19:04, 11 months 12 days ago EMA Grants Orphan Drug Status to AB8939 for AML Treatment AB Science AB8939 EMA Approval Acute Myeloid Leukemia Orphan Designation
BRIEF published on 04/23/2025 at 19:04, 11 months 12 days ago L'EMA accorde le statut de médicament orphelin à AB8939 pour le traitement de la LAM AB Science AB8939 Approbation De L'EMA Leucémie Myéloïde Aiguë Désignation D'orphelin
PRESS RELEASE published on 04/23/2025 at 18:59, 11 months 12 days ago AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia AB Science's AB8939 granted orphan drug designation by EMA in EU for treating acute myeloid leukemia, showing significant benefit over current therapies. Preclinical data reveals efficacy and safety Orphan Drug Designation AB Science EMA AB8939 Acute Myeloid Leukemia
PRESS RELEASE published on 04/23/2025 at 18:59, 11 months 12 days ago La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue La molécule AB8939 obtient la désignation de médicament orphelin dans l'Union Européenne pour le traitement de la leucémie myéloïde aigüe. AB Science fait un pas important dans le domaine de la recherche médicale Traitement AB Science Médicament Orphelin AB8939 Leucémie Myéloïde Aiguë
Published on 04/02/2026 at 22:00, 3 days 14 hours ago Star Copper Announces Closing of Charity Flow-Through Unit Private Placement
Published on 04/02/2026 at 18:32, 3 days 17 hours ago Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Published on 04/02/2026 at 15:00, 3 days 21 hours ago Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Published on 04/02/2026 at 14:40, 3 days 21 hours ago Northfield Capital Completes Acquisition Of Additional Interest In Juno Corp. And Announces Issuance Of Class B Multiple Voting Shares
Published on 04/02/2026 at 14:30, 3 days 21 hours ago Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution
Published on 04/06/2026 at 10:05, 2 hours 11 minutes ago K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models
Published on 04/06/2026 at 09:05, 3 hours 11 minutes ago McDonald's Türkiye Launches Campaign Spotlighting Driving Safety
Published on 04/04/2026 at 10:07, 2 days 2 hours ago Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
Published on 04/04/2026 at 02:05, 2 days 10 hours ago Blokees made its debut at 2026 Thailand Toy Expo, exhibiting multiple products
Published on 04/03/2026 at 18:00, 2 days 18 hours ago IEVA GROUP: IMPLEMENTATION OF A LIQUIDITY AGREEMENT WITH CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 18:46, 2 days 17 hours ago Disclosure of Share Capital and Voting Rights as of March 31, 2026
Published on 04/03/2026 at 18:46, 2 days 17 hours ago Déclaration du nombre d’actions et droits de vote au 31 mars 2026
Published on 04/03/2026 at 18:01, 2 days 18 hours ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 2 days 18 hours ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 2 days 18 hours ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 mars 2026